30 related articles for article (PubMed ID: 21617237)
1. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Murtaza M; Dawson SJ; Pogrebniak K; Rueda OM; Provenzano E; Grant J; Chin SF; Tsui DWY; Marass F; Gale D; Ali HR; Shah P; Contente-Cuomo T; Farahani H; Shumansky K; Kingsbury Z; Humphray S; Bentley D; Shah SP; Wallis M; Rosenfeld N; Caldas C
Nat Commun; 2015 Nov; 6():8760. PubMed ID: 26530965
[TBL] [Abstract][Full Text] [Related]
2. Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.
Ye H; Tong J; Liu J; Lin W; Zhang C; Chen K; Zhao J; Zhu W
Oncotarget; 2016 Jul; 7(28):43762-43778. PubMed ID: 27248325
[TBL] [Abstract][Full Text] [Related]
3. Different outcome variables yield different results!
Brouckaert O; Wildiers H; Neven P
Ann Oncol; 2013 Feb; 24(2):554. PubMed ID: 23277485
[No Abstract] [Full Text] [Related]
4. Reply to 'Different outcome variables yield different results', by O. Brouckaert et al.
Truin W; Voogd AC; Roumen RMH
Ann Oncol; 2013 Feb; 24(2):555. PubMed ID: 23341480
[No Abstract] [Full Text] [Related]
5. Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer.
Khan AM; Arjyal L; Shamaileh L; Simon M
BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36319039
[TBL] [Abstract][Full Text] [Related]
6. Off-Label Medication: From a Simple Concept to Complex Practical Aspects.
Rusz CM; Ősz BE; Jîtcă G; Miklos A; Bătrînu MG; Imre S
Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639747
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.
Wang S; Scharadin TM; Zimmermann M; Malfatti MA; Turteltaub KW; de Vere White R; Pan CX; Henderson PT
Chem Res Toxicol; 2018 Dec; 31(12):1293-1304. PubMed ID: 30381944
[TBL] [Abstract][Full Text] [Related]
8. Off-label use of cancer therapies in women diagnosed with breast cancer in the United States.
Hamel S; McNair DS; Birkett NJ; Mattison DR; Krantis A; Krewski D
Springerplus; 2015; 4():209. PubMed ID: 25977897
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.
Njiaju UO; Tevaarwerk AJ; Kim K; Chang JE; Hansen RM; Champeny TL; Traynor AM; Meadows S; Van Ummersen L; Powers K; Stewart JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):613-8. PubMed ID: 23228989
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.
Caruba T; Cottu PH; Madelaine-Chambrin I; Espié M; Misset JL; Gross-Goupil M
Breast J; 2007; 13(2):165-71. PubMed ID: 17319858
[TBL] [Abstract][Full Text] [Related]
12. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Scheithauer W; Van Cutsem E
Colorectal Dis; 2003 Nov; 5 Suppl 3():36-44. PubMed ID: 23573559
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
14. Off-label use of oxaliplatin in patients with metastatic breast cancer.
Delpeuch A; Leveque D; Rob L; Bergerat JP
Anticancer Res; 2011 May; 31(5):1765-7. PubMed ID: 21617237
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
